ArriVent BioPharma, Inc. filings document a Nasdaq-listed clinical-stage oncology company with common stock registered under the Exchange Act. Its Form 8-K reports cover financial results, Regulation FD disclosures, clinical and preclinical program announcements, conference presentations, IND-related updates, material-event disclosures, and exhibits tied to press releases.
Proxy materials describe stockholder voting matters, board elections, auditor ratification, annual meeting procedures, and governance information. The filing record also reflects capital-structure disclosures, emerging growth company status, material agreements, and risk-oriented disclosures associated with ArriVent's firmonertinib program and antibody-drug conjugate pipeline.
ArriVent BioPharma director John Hohneker received a non-qualified stock option grant on June 18, 2025. The key details of this insider transaction include:
- Granted 15,502 stock options to purchase common stock
- Exercise price set at $24.89 per share
- Options become exercisable on June 18, 2026
- Options expire on June 17, 2035
- Total cost basis of $0.00 as this was a compensation grant
The transaction was reported via Form 4 filing and executed through attorney-in-fact James Kastenmayer. This equity-based compensation aligns the director's interests with shareholders and represents a standard component of non-employee director compensation.
ArriVent BioPharma director Chris Nolet received a new stock option grant on June 18, 2025. The transaction details include:
- Granted 15,502 non-qualified stock options to purchase common stock
- Exercise price set at $24.89 per share
- Options become exercisable on June 18, 2026
- Options expire on June 17, 2035
- Zero cost basis for the options grant
This Form 4 filing, signed by James Kastenmayer as attorney-in-fact, represents a standard director compensation equity grant. The options provide Nolet with long-term alignment with shareholder interests through a 10-year exercise window, subject to a one-year vesting requirement.